Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 1/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.41 |
| ▸ | BUB1 | O43683 | 12/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 4/20 | 0.36 |
| ▸ | RAB9A | P51151 | 4/20 | 0.36 |
| ▸ | TP53 | P04637 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6093288 | 0.89 | ROCK2 (0.39) | HCAR3BUB1ROCK2ROCK1NPC1 | |
| SCHEMBL6092075 | 0.87 | HCAR3 (0.40) | HCAR3BUB1ROCK2ROCK1NPC1 | |
| SCHEMBL6394774 | 0.86 | ROCK2 (0.42) | BUB1ROCK2ROCK1NPC1RAB9A | |
| SCHEMBL6093483 | 0.86 | HCAR3 (0.43) | HCAR3BUB1ROCK2ROCK1ALDH1A1 | |
| SCHEMBL6095310 | 0.86 | HCAR3 (0.42) | HCAR3ROCK2ROCK1NPC1RAB9A | |
| SCHEMBL6093234 | 0.85 | KMT2A (0.46) | BUB1ROCK2ROCK1NPC1RAB9A | |
| SCHEMBL6093985 | 0.83 | ROCK2 (0.35) | BUB1ROCK2ROCK1NPC1RAB9A | |
| SCHEMBL6092785 | 0.82 | KIT (0.41) | BUB1ROCK2ROCK1ALDH1A1MEN1 | |
| SCHEMBL6092453 | 0.81 | HTR2C (0.44) | BUB1ROCK2ROCK1NPC1RAB9A | |
| SCHEMBL6092190 | 0.81 | BUB1 (0.47) | BUB1NPC1RAB9ATP53ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109351-B1 | Fused pyrrolecarboxamides; GABA brain receptor ligands | NEUROGEN CORPORATION (US) | 2006-09-19 | — | — | US | disclosed |
| US-20050014939-A1 | Fused pyrrolecarboxamides: GABA brain receptor ligands | NEUROGEN CORPORATION | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014939-A1 | Fused pyrrolecarboxamides: GABA brain receptor ligands | GABRB2, GABRB1, GABRB3 | HCAR3 113/4885HCAR2 52/4885BUB1 2287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.